TNF receptor-associated factor 1 (TRAF1) (TRAF1)

TNF receptor-associated factor 1 (TRAF1) is a cytoplasmic adapter protein that mediates signal transduction from various members of the tumor necrosis factor receptor (TNFR) superfamily, including TNFR2, CD40, and 4-1BB (UniProt Q13077; NCBI Gene 7185). Unlike most other TRAF family members, TRAF1 lacks the N-terminal RING finger domain, which is typically responsible for E3 ubiquitin ligase activity; instead, it functions primarily by forming heterodimers with TRAF2 to modulate downstream signaling pathways, including NF-kappaB and JNK (Bradley & Pober, 2001). TRAF1 is a critical regulator of cell survival, inflammation, and the immune response, particularly within the lymphoid system (Zhu et al., 2014). In clinical contexts, TRAF1 is frequently overexpressed in B-cell malignancies like chronic lymphocytic leukemia (CLL) and various lymphomas, where it contributes to tumor cell survival and resistance to chemotherapy-induced apoptosis (Edawa et al., 2020). Additionally, genetic variations in the TRAF1/C5 locus are strongly linked to an increased risk and severity of rheumatoid arthritis (Kurreeman et al., 2007). Because of its role in promoting pro-survival and pro-inflammatory signaling, TRAF1 mRNA is being investigated as a therapeutic target using RNA-based technologies like small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) to downregulate its expression and restore apoptotic sensitivity in cancer cells or reduce inflammation in autoimmune diseases (Park et al., 2021).

Other names

EBP60Epstein-Barr virus-induced protein 60MGC:10353TNF receptor-associated factor 1

Targeted degradation of TRAF1 mRNA via RNA interference (siRNA) or antisense oligonucleotide (ASO) binding, which prevents the translation of the TRAF1 protein and subsequently inhibits pro-survival and pro-inflammatory signaling pathways.